<DOC>
	<DOC>NCT02068287</DOC>
	<brief_summary>Beta adrenergic system, over-activated in septic shock patients, is a key modulator of the inflammatory response. Experimental works demonstrated that Esmolol, an highly selective beta-1 blocker, reduces heart rate and regulates the inflammatory response. A recent mono centric, double blind, randomized clinical work in septic shock patients has shown that Esmolol administration is safe and reduces effectively heart rate. However there are only sparse data on 1) regional and micro-circulation, 2) inflammation modulation in human resuscitated septic shock patients treated by esmolol.</brief_summary>
	<brief_title>Esmolol Effects on Heart and Inflammation in Septic Shock</brief_title>
	<detailed_description />
	<mesh_term>Shock</mesh_term>
	<mesh_term>Shock, Septic</mesh_term>
	<mesh_term>Esmolol</mesh_term>
	<criteria>septic shock patients following the definition of the Surviving Sepsis Campaign femoral and central venous catheters for thermodilution monitoring fluid optimization with a cardiac index &gt; 3 l/min/m2 Heart Rate &gt;100 /min Cardiogenic shock Bradycardia History of Severe Asthma Indications against esmolol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Septic Shock</keyword>
	<keyword>Hemodynamic</keyword>
	<keyword>Inflammatory status</keyword>
	<keyword>Beta adrenergic modulation</keyword>
	<keyword>Esmolol</keyword>
</DOC>